Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-04-13Clinical Trial Update: AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders [NA]
This clinical trial update reports on allogeneic hematopoietic cell transplantation from matched unrelated donors in patients with advanced …
-
CLINICAL_TRIALS trial_result · 2023-04-03Clinical Trial Update: The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
A completed clinical trial study (MDS-TAO) focused on transplantation outcomes in myelodysplastic syndromes with results posted in 2023.
-
CLINICAL_TRIALS trial_result · 2023-03-30Clinical Trial Update: A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS [Phase 1, Phase 2]
Phase 1/2 trial of TP-0184 for anemia in adults with IPSS-R low or intermediate-risk myelodysplastic syndromes was terminated; results poste…
-
CLINICAL_TRIALS trial_result · 2023-03-23Clinical Trial Update: Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation [Phase 3]
This clinical trial update reports results from a Phase 3 study of ivosidenib combined with azacitidine versus placebo in previously untreat…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT [Phase 2, Phase 3]
Phase 2/Phase 3 trial assessing CD45RA-depleted T-cell infusion to prevent infections after TCRab/CD19-depleted allogeneic hematopoietic ste…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant [Phase 2, Phase 3]
A Phase 2/3 clinical trial comparing thymoglobulin to alemtuzumab in patients undergoing allogeneic stem cell transplantation has been compl…
-
CLINICAL_TRIALS trial_result · 2023-02-16Clinical Trial Update: Panobinostat Maintenance After HSCT fo High-risk AML and MDS [Phase 3]
Phase 3 trial update on panobinostat maintenance after stem cell transplant in high-risk AML and MDS was terminated.
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies [Phase 1, Phase 2]
Phase 1/2 trial of ProTmune for allogeneic hematopoietic cell transplantation in adults with hematologic malignancies completed; results pos…
-
CLINICAL_TRIALS trial_result · 2023-02-01Clinical Trial Update: Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]
Phase 1/2 trial investigating cytokine-induced memory-like NK cells in patients with acute myeloid leukemia or myelodysplastic syndrome; stu…
-
CLINICAL_TRIALS trial_result · 2022-12-27Clinical Trial Update: Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating clofarabine, melphalan, and thiotepa followed by donor stem cell transplant for high-risk hematologic …
-
CLINICAL_TRIALS trial_result · 2022-12-16Clinical Trial Update: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation [Phase 3]
A Phase 3 randomized trial comparing Fludarabine and Busulfan versus Fludarabine, Busulfan plus Total Body Irradiation in patients with myel…
-
CLINICAL_TRIALS trial_result · 2022-12-08Clinical Trial Update: Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [Phase 2]
Phase 2 trial update on conditioning regimens for transplantation of unrelated donor umbilical cord blood in patients with hematologic malig…
-
CLINICAL_TRIALS trial_result · 2022-11-14Clinical Trial Update: Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) [Phase 3]
Phase 3 trial evaluating Efprezimod Alfa (CD24Fc, MK-7110) for prevention of acute graft-versus-host disease after myeloablative HSCT; study…
-
CLINICAL_TRIALS trial_result · 2022-11-04Clinical Trial Update: Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) [Phase 2]
Phase 2 clinical trial evaluating hypomethylating effects of freeze-dried black raspberries in patients with myelodysplastic syndromes.
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS [Phase 3]
Phase 3 trial comparing NiCord (omidubicel) stem cell transplantation to standard umbilical cord blood in patients with hematologic malignan…
-
CLINICAL_TRIALS trial_result · 2022-10-21Clinical Trial Update: A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS [Phase 1, Phase 2]
A phase 1b/2 trial evaluating alvocidib in combination with decitabine or azacitidine in myelodysplastic syndromes was terminated; results w…
-
CLINICAL_TRIALS trial_result · 2022-09-22Clinical Trial Update: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) [Phase 3]
This Phase 3 trial compares pevonedistat plus azacitidine versus azacitidine alone as first-line therapy for higher-risk myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating a combined regimen including iodine-131 monoclonal antibody BC8, fludarabine phosphate, total body irradia…
-
CLINICAL_TRIALS trial_result · 2022-07-19Clinical Trial Update: Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole [Phase 2]
A Phase 2 clinical trial evaluating peripheral blood stem cell transplantation from family haploidentical donors in patients with myelodyspl…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: Prophylactic Application of Donor-derived TCM After Allogeneic HSCT [Phase 1, Phase 2]
A Phase 1/2 clinical trial investigated prophylactic use of donor-derived TCM after allogeneic hematopoietic stem cell transplantation, comp…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) [Phase 3]
Phase 3 trial results for APR-246 (eprenetapopt) in combination with azacitidine for TP53-mutant myelodysplastic syndromes have been complet…
-
CLINICAL_TRIALS trial_result · 2022-07-12Clinical Trial Update: Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant [Phase 1, Phase 2]
Clinical trial update for a phase 1/2 study evaluating gene-modified donor T-cells after TCR alpha beta–negative depleted stem cell transpla…
-
CLINICAL_TRIALS trial_result · 2022-07-07Clinical Trial Update: CPX-351 in Higher Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 trial updates for CPX-351 in higher-risk myelodysplastic syndromes have been completed.
-
CLINICAL_TRIALS trial_result · 2022-05-26Clinical Trial Update: Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. [Phase 2]
A phase 2 prospective open-label single-arm trial evaluating hetrombopag for lower-risk myelodysplastic syndromes with thrombocytopenia.
-
CLINICAL_TRIALS trial_result · 2022-04-20Clinical Trial Update: RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT [Phase 2]
Phase 2 clinical trial update on a RIC regimen for low- and intermediate-risk myelodysplastic syndromes undergoing haploidentical hematopoie…